Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05696782 · ClinicalTrials.gov registry record · Phase 2
Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer (Stage III) and Non-small Cell Lung Cancer Stage II, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT05696782: Recruiting Phase 2 study of Non-Small Cell Lung Cancer (Stage III) and Non-small Cell Lung Cancer Stage II, sponsored by Wake Forest University Health Sciences.
NCT05696782 is a Phase 2 study of Non-Small Cell Lung Cancer (Stage III) and Non-small Cell Lung Cancer Stage II that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 28 participants, below the 85-participant average among 8 other Non-Small Cell Lung Cancer (Stage III) trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05696782, a Phase 2 study of Non-Small Cell Lung Cancer (Stage III) and Non-small Cell Lung Cancer Stage II, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study aims to determine what effects (good and bad) Durvalumab has on participants and their cancer with a "quick start" of Durvalumab within 14 days of finishing chemotherapy and radiation. The study will also determine the logistic barriers to the quick start of Durvalumab.
Primary Outcome
Fidelity is defined as a dichotomous composite indicator (yes/no) that describes whether the patient received very early (1-7 days) or early (days 8-14 days) initiation of Durvalumab as per protocol with all four of the following criteria having been met: (i) CT chest obtained after the last day of radiation therapy and before the first infusion of Durvalumab, (ii) first infusion within 14 days of completing radiation therapy, (iii) second and third doses received within 63 days of the first dos
Conditions Studied
Interventions
- DRUG Durvalumab
- OTHER the EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30)
- DIAGNOSTIC_TEST COPD Assessment Test (CAT)
- DIAGNOSTIC_TEST Modified Medical Research Council (mMRC) dyspnea scale
Study Locations (1)
North Carolina
- Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-07-26 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
What NCT05696782 shows while recruiting
NCT05696782 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 85-participant average among 8 other Non-Small Cell Lung Cancer (Stage III) trials with a reported enrollment target (67% lower).
The record links to 3 conditions, with Non-Small Cell Lung Cancer (Stage III) appearing as the primary indexed condition, and to 4 interventions - of which Durvalumab is the first listed.
NCT05696782 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05696782 about?
NCT05696782 is a clinical study titled "Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer". This research study aims to determine what effects (good and bad) Durvalumab has on participants and their cancer with a "quick start" of Durvalumab within 14 days of finishing chemotherapy and radiation. The study will also determine the logistic barriers to the quick start of Durvalumab.
What is the current status of trial NCT05696782?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2023-07-26. Estimated completion is 2027-04.
What conditions does trial NCT05696782 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer (Stage III), Non-small Cell Lung Cancer Stage II, Unresectable Non-Small Cell Lung Carcinoma.
What interventions are being tested in trial NCT05696782?
The interventions under investigation include: Durvalumab (DRUG), the EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30) (OTHER), COPD Assessment Test (CAT) (DIAGNOSTIC_TEST), Modified Medical Research Council (mMRC) dyspnea scale (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05696782?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05696782 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer (Stage III)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05696782's enrollment target sits among peer trials
28 7th of 8 higher than 2 of 8 other Non-Small Cell Lung Cancer (Stage III) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer (Stage III) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
HEARTS Trial for Thoracic Cancers
RECRUITING · Phase 2
-
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
RECRUITING · Phase 2
-
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
RECRUITING · Phase 2
-
Pulmonary Rehabilitation in Advanced Lung Cancer Survivors
RECRUITING · Phase 2
-
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement
RECRUITING · Phase 2
-
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI